Blood Pressure Control May Help Mitigate Dementia Risk From Hypertension
Researchers sought to assess the age at which the population attributable fraction of dementia from hypertension would be the highest.
Researchers sought to assess the age at which the population attributable fraction of dementia from hypertension would be the highest.
Donanemab is an antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
In an international meta-analysis, researchers evaluated sex differences in all-cause dementia risk across diverse ethno-regional groups.
Researchers sought to assess the role of APOE genotype and age at HRT initiation on the heterogeneity in cognitive response to HRT.
These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.
The sNDA is supported by data from two phase 3 studies that evaluated the efficacy and safety of brexpiprazole in patients with agitation associated with Alzheimer dementia.
In a meta-analysis, researchers estimated the prevalence of dementia in a centenarian and near-centenarian population and identified the risk and protective factors for dementia.
Researchers sought to analyze brain concentrations of vitamin D and assess whether there were any associations with cognitive and neuropathology outcomes.
Research findings support the use of vitamin D supplementation to help slow cognitive decline in Alzheimer dementia and reduce Parkinson disease symptom severity.
Gantenerumab is an investigational immunoglobulin G1 antibody designed to increase the clearance of soluble amyloid beta from the brain.